ASTELLAS PHARMA (Germany) Top Insiders
YPHA Stock | EUR 9.45 0.10 1.07% |
Examination of ASTELLAS PHARMA's management performance can provide insight into the company performance.
ASTELLAS |
Symbol | YPHA |
Name | ASTELLAS PHARMA UNSPADR |
Type | Stock |
Country | Germany |
Exchange | F |
Information on ASTELLAS PHARMA UNSPADR Leadership is currently not available.
If you believe this information is not accurate please let us know and we will check it out. Check all delisted instruments across multiple markets.Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Thematic Opportunities
Explore Investment Opportunities
ASTELLAS PHARMA Management Team Effectiveness
The company has return on total asset (ROA) of 0.0635 % which means that it generated a profit of $0.0635 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0971 %, meaning that it generated $0.0971 on every $100 dollars invested by stockholders. ASTELLAS PHARMA's management efficiency ratios could be used to measure how well ASTELLAS PHARMA manages its routine affairs as well as how well it operates its assets and liabilities.ASTELLAS PHARMA Workforce Comparison
ASTELLAS PHARMA UNSPADR is rated first in number of employees category among its peers. The total workforce of Drug Manufacturers—General industry is at this time estimated at about 21,959. ASTELLAS PHARMA totals roughly 14,522 in number of employees claiming about 66% of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of 0.11 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.18 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.18. ASTELLAS PHARMA UNSPADR Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. ASTELLAS PHARMA UNSPADR Price Series Summation is a cross summation of ASTELLAS PHARMA price series and its benchmark/peer.
About ASTELLAS PHARMA Management Performance
The success or failure of an entity such as ASTELLAS PHARMA UNSPADR often depends on how effective the management is. ASTELLAS PHARMA management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ASTELLAS management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ASTELLAS management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 15455 people.
Complementary Tools for ASTELLAS Stock analysis
When running ASTELLAS PHARMA's price analysis, check to measure ASTELLAS PHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ASTELLAS PHARMA is operating at the current time. Most of ASTELLAS PHARMA's value examination focuses on studying past and present price action to predict the probability of ASTELLAS PHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ASTELLAS PHARMA's price. Additionally, you may evaluate how the addition of ASTELLAS PHARMA to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |